Articles tagged with Cancer Patients
A large-scale study found that low-dose CT screening increases the 20-year survival rate of lung cancer patients from 18.6% to 81%, with Stage I cancers having an even higher long-term survival rate of 95%. Early detection through annual screening can effectively cure lung cancer in the long term.
New research suggests that vitamin D supplements can reduce the risk of peripheral neuropathy in patients undergoing paclitaxel treatment. The study found that patients with vitamin D deficiency were more likely to experience severe neuropathy, and that inducing vitamin D deficiency caused similar symptoms in a mice model study.
A study published in Oncotarget reveals that HER2 mutant alleles play a crucial role in determining treatment response to neratinib and poziotinib. Researchers found that individual HER2 mutant alleles have distinct effects on therapeutic efficacy, suggesting new targets for breast cancer therapy.
Researchers describe the use of ripretinib and repeated surgical resection in a patient with recurrent GIST harboring a KIT exon 11 mutation. The treatment led to extended clinical benefit, outperforming current reported data from ripretinib clinical trials.
A phase 1 trial of the radiopharmaceutical 225AC-J591 demonstrated promising antitumor activity against advanced metastatic prostate cancer, reducing PSA levels by at least half for 47% of patients. The treatment was well-tolerated, with only temporary low blood cell count side effects.
Bioethics researchers at Dana-Farber Cancer Institute warn that patient-facing AI can depersonalize care and erode relationships between patients and caregivers. The authors advocate for principles such as human dignity, patient autonomy, and regulatory oversight to ensure AI-driven healthcare is ethically sound and equitable.
Researchers have discovered a novel biomarker that enables the evaluation of near-infrared photoimmunotherapy (NIR-PIT) treatment success. The biomarker uses microbubbles to track tumor vessels and measure the effectiveness of NIR-PIT, which combines antibodies and near-infrared light to destroy cancer cells.
A UCLA-led study shows datopotamab deruxtecan, a Trop-2 directed antibody-drug conjugate, significantly improves progression-free survival in patients with metastatic non-small cell lung cancer. The treatment primarily benefits patients with non-squamous tumors, reducing disease progression and improving overall survival.
A study of 9,479 participants identified racial and ethnic disparities in breast cancer survival, highlighting the need for targeted interventions to improve outcomes for at-risk subgroups. The findings suggest that focused care approaches can address these disparities and promote more equitable treatment.
A clinical trial in Spain found that only 1 in 3 family members of patients with colorectal cancer participate in screening, missing opportunities for early detection. The study used fecal testing and colonoscopy to screen first-degree relatives, but uptake was low.
A clinical trial shows that a combination of atezolizumab and bevacizumab can reduce cancer recurrence in liver cancer patients by one-third after curative-intent resection or ablation. The therapy has improved recurrence-free survival rates compared to active surveillance, offering new hope for these patients.
A study published in CANCER reveals that individuals with diabetes, especially those with diabetic complications, have a higher risk of dying early from colorectal cancer. Patients with complicated diabetes had an 85% higher odds of death from any cause and 41% higher odds of death from cancer.
Researchers saw a major pathologic response in over half of surgical specimens from patients treated with neoadjuvant pembrolizumab. The treatment shrank over half of advanced melanomas, according to exploratory analyses presented at the European Society of Medical Oncology (ESMO) Congress 2023.
A clinical trial has shown that combining chemotherapy with immunotherapy nivolumab significantly improved outcomes in patients with advanced bladder cancer. The study found nearly twice as many patients with no evidence of disease after treatment, and a median complete response of 37.1 months.
A new drug, cabozantinib, has shown positive results in a clinical trial involving patients with advanced neuroendocrine tumors. The study found that patients treated with cabozantinib survived significantly longer without their disease worsening compared to those who received a placebo. This novel treatment strategy targets angiogenes...
A phase III pivotal trial evaluating cabozantinib in advanced neuroendocrine tumors demonstrated significant improvements in median progression-free survival (PFS) compared to placebo. The study met its primary objective for both cohorts of patients, providing encouraging news for those with progressive disease.
A phase 3 clinical trial found belzutifan significantly reduces the risk of progression in patients with metastatic clear cell renal cell carcinoma who had previously treated with immune checkpoint inhibitors and anti-angiogenic therapies. The drug demonstrated improved progression-free survival, higher overall response rates, and redu...
A secondary analysis of the SWOG S0931 trial found that patients with very-high risk clear-cell renal cell carcinoma who received adjuvant everolimus after surgery had a statistically significant improvement in recurrence-free survival. The results suggest that everolimus may be beneficial for this high-risk patient population, but als...
Researchers found that tumour cells escape immunotherapy by losing or changing BCMA and GPRC5D targets on their surface. This understanding has led to the suggestion of periodically profiling myeloma cells throughout a patient's treatment course to adapt treatment strategies.
Researchers found that online educational materials about breast surgery have a negative tone, exceed recommended reading levels, and are of poor quality. Studies assessed readability, bias, quality, and tone using validated tools, highlighting the need for accessible materials.
A new AI-based tool estimates patient-specific cancer survival rates using machine learning, offering personalized prognosis for patients with breast, thyroid, and pancreatic cancers. The Cancer Survival Calculator differs from existing estimators by incorporating multiple factors beyond disease stage.
Researchers are testing a single target to weaken tumors and strengthen immune cells in pediatric brain tumor patients. The goal is to improve the effectiveness of CAR-T therapy, which has shown promise but also leads to exhaustion of immune cells.
A new study found that ide-cel, a CAR T-cell therapy, showed similar survival outcomes for Black and white patients with multiple myeloma. Researchers hope this finding encourages the use of ide-cel in all patients with multiple myeloma.
Researchers discovered that lactate-producing intratumoral bacteria drives resistance to radiation therapy. Cancer cells respond to radiation by rewiring metabolic signaling pathways using lactic acid instead of glucose.
A study by researchers at Keck School of Medicine of USC found that Black cancer survivors experience slowdowns in diagnosis and delivery of care due to exposure to racial discrimination. Positive interactions, such as ready access to providers and displays of empathy, were identified as key factors in improving care.
A simple MRI scan and a new metric for prostatic urethra length may help identify men at risk of chronic urinary side effects after radiation therapy. The study found that longer prostatic urethras are associated with a higher likelihood of these symptoms, which can impact quality of life.
In a phase I trial, an oncolytic virus treatment designed by Brigham researchers extended survival among patients with recurrent glioblastoma, especially those with pre-existing viral antibodies. The therapy reshaped the tumor's surrounding environment to stimulate an anti-tumor immune response.
Dana-Farber Cancer Institute presents several studies on novel treatments, combination therapies, and personalized medicine for lung, kidney, and neuroendocrine tumors. The studies include pivotal trials on adagrasib with pembrolizumab for non-small cell lung cancer and belzutifan versus everolimus for clear cell renal cell carcinoma.
Researchers will study the impact of exercise, intermittent fasting, and their combination on fatigue, biomarkers of inflammation, and quality of life in women with advanced breast cancer. The trial aims to improve treatment tolerability and possibly life duration for these patients.
A team of researchers has developed a new visualization tool combining high-speed cameras and fluorescent injection to distinguish tumor tissue from normal tissue across cancer types. The technique, known as fluorescence lifetime (FLT) imaging, achieved an accuracy of over 97% in distinguishing tumor tissue from healthy tissue.
A Rutgers study examines how oncology doctors facilitate psychological well-being, finding that providers who show more empathy promote better psychological health among breast cancer patients. The research also highlights the importance of addressing uncertainty throughout the cancer trajectory to facilitate psychological adjustment.
A new study published in JNCCN found that intensive local-regional treatment to remove as much tumor as possible did not significantly impact overall quality of life for patients with metastatic colorectal cancer. However, the treatment was associated with a higher risk of adverse events.
A multilevel primary care intervention, including electronic health record reminders and patient outreach, improved timely follow-up of overdue abnormal cancer screening test results for breast, cervical, colorectal, and lung cancer. The intervention was found to be effective in reducing missed screenings.
A new blood test called OvaPrint TM detects specific nucleic acids in the blood, distinguishing between cancerous and benign pelvic masses with high accuracy. The test has the potential to improve treatment outcomes by identifying the best surgical approach for patients with a pelvic mass.
The study developed a highly accurate AI model for fully automated cancer detection, including small and difficult-to-detect tumors. The model could detect visually imperceptible cancer from normal-appearing pancreases substantially early before clinical diagnosis, with a median of 438 days.
A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.
Researchers discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs), with encouraging results from phase II basket studies demonstrating activity in platinum-sensitive relapsed SCLC and other malignancies. Lurbinectedin's mechanism of action involves inhibiting oncogenic transcription, promoting apoptosis and cell death.
Researchers identified a circulating tumor DNA (ctDNA) biomarker that can predict disease recurrence and response to treatment in patients with BRAF-negative melanoma. The study found that measuring ctDNA levels and variants can help tailor therapy and improve patient outcomes.
A team of researchers at Mays Cancer Center has identified protein markers that could signal the early development of metastatic lung cancer. These markers have led to a $1.6 million grant and will pave the way for a clinical trial in patients with advanced lung cancer.
Researchers found that relying on existing diagnostic CT scans instead of new ones for simple palliative radiation treatments reduced patient wait times from nearly five hours to under 30 minutes. This novel workflow can improve the patient experience and reduce costs, making it a promising approach for expedited care.
Researchers have developed a new approach to treating invasive bladder cancer, combining chemotherapy and immunotherapy, which may preserve quality of life. In a phase 2 clinical trial, approximately 43% of patients achieved complete response without surgical removal of the bladder.
Men with metastatic prostate cancer in Sweden experienced an average survival rate increase of six months after dual treatment was introduced from 2016 onwards. This improvement coincides with the gradual rollout of 'dual treatment', combining standard hormone therapy and chemotherapy or androgen receptor blockers.
A new study found that a shorter radiation treatment course is just as effective as a longer schedule for patients with non-HPV-related locally advanced disease. Delivering fewer, but higher doses of radiation was associated with similar tumor control and late-term side effects.
A novel liquid biopsy test identifies levels of circulating tumor DNA as a more precise measure of disease burden than the number of tumors themselves. Patients with lower levels of detectable ctDNA are more likely to benefit from radiation therapy.
A randomized study shows that shorter radiation therapy courses are just as effective in preventing cancer return and reducing side effects for patients with breast reconstruction. The accelerated treatment regimen saved patients time, money, and experienced fewer treatment breaks.
A multi-center study found that stereotactic body radiotherapy (SABR) can achieve 100% local control and cancer-specific survival for longer than three years among patients with inoperable kidney cancer. The treatment was effective in preserving kidney function, with only one patient requiring dialysis.
Patients who engage in regular sexual activity or vaginal dilation have a lower risk of long-term side effects, including vaginal stenosis. Regular dilation and/or sex were associated with lower risk of moderate-grade vaginal shortening and narrowing five years after treatment.
A new study found that precision medicine navigators can significantly increase genomic testing rates for Black patients with prostate cancer. Genomic testing is used to gauge the likelihood of cancer metastasis and has been shown to be more accurate than traditional tests in predicting treatment outcomes.
Two liquid biopsy tests identified patients with a high risk of cervical cancer recurrence after chemoradiation treatment, allowing for earlier detection and potential improvement in outcomes. The tests detected HPV ctDNA in the blood of patients with residual disease, providing insight before tissue biopsy becomes possible.
A new size threshold for retropharyngeal lymph nodes is proposed to improve risk stratification and treatment decisions in patients with nasopharyngeal carcinoma. Using a 6-mm threshold, the study found significant differences in overall survival between stage-I and stage-II disease.
Cancer researchers at University of Cincinnati Cancer Center are exploring a new method called lattice therapy, which delivers higher doses to tumors and lower doses to surrounding tissues. The approach has shown promise in reducing treatment time and improving patient outcomes for head and neck, lung, and brain tumors.
A phase III trial suggests that fewer and higher doses of radiation therapy delivered over five sessions are as effective as lower doses delivered over several weeks for patients with locally advanced disease. The treatment achieved a 96% five-year disease control rate, comparable to 95% for conventional radiation.
A new drug called vorasidenib has been shown to significantly slow tumor growth and extend the average time until tumor growth in patients with grade 2 IDH-mutant gliomas. This breakthrough could offer a first early treatment option for these cancer patients, potentially improving their quality of life.
A new editorial paper highlights the importance of including older patients in lung cancer clinical trials, where they are often undertreated due to age-related factors. The paper emphasizes the need for increased collaboration among stakeholders to enhance enrollment and retention of older cancer patients.
The article discusses the need to reassess COVID-19 precautions in 2023, particularly for patients with hematologic malignancies. The researchers highlight the increased risk of poor response to vaccination and worse outcomes from COVID-19 infection among these patients.
Researchers have identified a specific error in the NOTCH1 gene that causes rare kidney cancer reninoma. The study found that using existing drugs targeting this gene could serve as an alternative treatment for patients where surgery is not recommended.
A new MU study found that APRNs recognize the importance of breast cancer survivorship care and can benefit from standardized education. The findings suggest that formalizing education on breast cancer survivorship could lead to improved healthcare for patients, including symptom management, monitoring, and follow-up appointments.
Researchers developed a scoring system analyzing income, education, geographical location, access to care, and other factors to identify patients at increased risk of poor outcomes. The study found significant socioeconomic disadvantage associated with a 21% decrease in textbook outcomes and a 32% decrease in overall survival.
Researchers explore kinase inhibitors as targeted therapies for specific CRC subsets, offering hope for improved treatment options. Key findings suggest that uncovering essential kinases for tumor growth can lead to more effective treatment strategies in metastatic or later-stage CRC patients.
University of Queensland researchers have identified a novel molecule that could overcome cancer drug resistance and prevent tumour regrowth in cancer patients. The newly discovered molecule is not currently a target for treatment, opening the potential for new drug development to combat this major cause of death in cancer patients.